Sprout Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://addyi.com
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01188603
- Locations
- 🇺🇸
511.146.01005 Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States
🇺🇸511.146.01001 Boehringer Ingelheim Investigational Site, Kalamazoo, Michigan, United States
🇺🇸511.146.01004 Boehringer Ingelheim Investigational Site, Knoxville, Tennessee, United States
A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 596
- Registration Number
- NCT01103362
- Locations
- 🇺🇸
511.133.01050 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
🇺🇸511.133.01059 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
🇺🇸511.133.01064 Boehringer Ingelheim Investigational Site, Newark, Delaware, United States
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 748
- Registration Number
- NCT01057901
- Locations
- 🇺🇸
511.156.01046 Boehringer Ingelheim Investigational Site, Plantation, Florida, United States
🇺🇸511.156.01040 Boehringer Ingelheim Investigational Site, Statesville, North Carolina, United States
🇺🇸511.156.01072 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
- Conditions
- DepressionSexual Dysfunctions, Psychological
- Interventions
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 111
- Registration Number
- NCT01040208
- Locations
- 🇺🇸
Western Affiliated Research Institute, Denver, Colorado, United States
🇺🇸Albuquerque Neuroscience, Albuquerque, New Mexico, United States
🇺🇸Clinco, Terre Haute, Indiana, United States
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- Drug: placebo
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 949
- Registration Number
- NCT00996372
- Locations
- 🇺🇸
511.130.01041 Boehringer Ingelheim Investigational Site, New Britain, Connecticut, United States
🇺🇸511.130.01009 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸511.130.01013 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 1090
- Registration Number
- NCT00996164
- Locations
- 🇺🇸
511.147.01019 Boehringer Ingelheim Investigational Site, St. Petersburg, Florida, United States
🇺🇸511.147.01023 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸511.147.01055 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 480
- Registration Number
- NCT00601367
- Locations
- 🇫🇷
511.118.3310A Boehringer Ingelheim Investigational Site, Marseille, France
🇫🇷511.118.3311A Boehringer Ingelheim Investigational Site, Toulouse, France
🇫🇷511.118.3312A Boehringer Ingelheim Investigational Site, Marseille, France
Flibanserin Versus Placebo in Premenopausal Women With HSDD
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- Drug: 50 mg qhsDrug: 100 mgDrug: placebo
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 945
- Registration Number
- NCT00491829
- Locations
- 🇫🇷
511.77.3301A Boehringer Ingelheim Investigational Site, Bordeaux, France
🇫🇷511.77.3305A Boehringer Ingelheim Investigational Site, La Rochelle, France
🇧🇪511.77.32005 Boehringer Ingelheim Investigational Site, Gent, Belgium
A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 1723
- Registration Number
- NCT00441558
- Locations
- 🇨🇦
511.84.02015 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada
🇺🇸511.84.01198 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸511.84.01012 Boehringer Ingelheim Investigational Site, Seattle, Washington, United States
6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA
- Conditions
- Sexual Dysfunctions, Psychological
- Interventions
- Drug: placebo
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Sprout Pharmaceuticals, Inc
- Target Recruit Count
- 1385
- Registration Number
- NCT00360243
- Locations
- 🇺🇸
511.70.01009 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
🇺🇸511.70.01022 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸511.70.01057 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States